Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Metformin, a first line antihyperglycemic medication, is an AMPK activator and has been hypothesized to act as a geroprotective agent. Studies on its association with various classifications of age-related cognitive decline have shown mixed results with positive and negative findings.

Objective

To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia.

Method

Eligible research investigated the effect of metformin on dementia, Alzheimer's disease, or any measure of cognitive impairment compared to any control group who were not receiving metformin. The initial search resulted in 862 citations from which 14 studies (seven cohort, four cross-sectional, two RCTs, and one case control) were inc

SUBMITTER: Campbell JM 

PROVIDER: S-EPMC6218120 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature